Showing 2 posts of 2 posts found.
GlaxoSmithKline has withdrawn the US application for its restless legs syndrome treatment Solzira. The company, along with co-developer XenoPort, is …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
Artificial hearts: a century of innovation